In today’s session Ariad Pharmaceuticals, Inc. (ARIA) recorded an unusually high (607) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the October, 2016 put, expecting serious ARIA decrease. With 607 contracts traded and 15684 open interest for the Oct, 16 contract, it seems this is a quite bearish bet. The option with symbol: ARIA161021P00013500 closed last at: $1.1 or 69.2% up. About 667,316 shares traded hands. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has risen 98.63% since March 11, 2016 and is uptrending. It has outperformed by 93.17% the S&P500.
Analysts await Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) to report earnings on November, 1. They expect $-0.20 EPS, up 31.03% or $0.09 from last year’s $-0.29 per share. After $0.57 actual EPS reported by Ariad Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -135.09% negative EPS growth.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Ratings Coverage
Out of 5 analysts covering Ariad Pharmaceuticals (NASDAQ:ARIA), 4 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 80% are positive. $22 is the highest target while $5 is the lowest. The $13.71 average target is 4.34% above today’s ($13.14) stock price. Ariad Pharmaceuticals has been the topic of 9 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by SunTrust on Wednesday, October 5. The firm earned “Buy” rating on Wednesday, October 5 by Suntrust Robinson. On Wednesday, May 11 the stock rating was maintained by Barclays Capital with “Underweight”. The firm earned “Underweight” rating on Friday, July 29 by Barclays Capital. Leerink Swann initiated the shares of ARIA in a report on Monday, September 26 with “Outperform” rating. The stock has “Neutral” rating given by JP Morgan on Friday, August 7. The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) earned “Underweight” rating by Barclays Capital on Tuesday, January 19. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, March 9.
According to Zacks Investment Research, “Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.”
Insitutional Activity: The institutional sentiment increased to 1.4 in 2016 Q2. Its up 0.73, from 0.67 in 2016Q1. The ratio is positive, as 19 funds sold all Ariad Pharmaceuticals, Inc. shares owned while 44 reduced positions. 30 funds bought stakes while 58 increased positions. They now own 131.89 million shares or 0.58% less from 132.66 million shares in 2016Q1.
Swiss Comml Bank has invested 0% of its portfolio in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). Us Commercial Bank De holds 10,649 shares or 0% of its portfolio. Blackrock Incorporated owns 18,045 shares or 0% of their US portfolio. Trexquant Investment Lp accumulated 115,558 shares or 0.11% of the stock. Royal National Bank & Trust Of Canada has 64,190 shares for 0% of their US portfolio. Wells Fargo Mn accumulated 0% or 108,222 shares. Highvista Strategies Limited Company has invested 1.23% of its portfolio in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). Hanseatic Svcs Inc reported 96 shares or 0% of all its holdings. Js Cap Mngmt Lc last reported 1.15% of its portfolio in the stock. Adage Cap Prtn Group Lc has 0.01% invested in the company for 562,361 shares. Raymond James Fincl Services reported 28,336 shares or 0% of all its holdings. Financial Bank Of America De owns 146,645 shares or 0% of their US portfolio. Fifth Third Comml Bank last reported 1,500 shares in the company. Family Mgmt owns 179,515 shares or 0.75% of their US portfolio. Creative Planning reported 29,000 shares or 0% of all its holdings.
Insider Transactions: Since April 22, 2016, the stock had 1 insider buy, and 12 sales for $3.87 million net activity. The insider CLACKSON TIMOTHY P sold 18,286 shares worth $148,230. Another trade for 108,569 shares valued at $896,135 was sold by Radaelli Massimo. LAVIDAS ATHANESE sold $626,039 worth of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on Monday, June 13. 26,990 Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares with value of $199,996 were bought by Panayiotopoulos Paris.
ARIAD Pharmaceuticals, Inc. is an oncology company. The company has a market cap of $2.59 billion. The Firm is focused on transforming the lives of cancer patients with medicines. It currently has negative earnings. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus.
ARIA Company Profile
ARIAD Pharmaceuticals, Inc. (ARIAD), incorporated on April 12, 1991, is an oncology company. The Firm is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus.
More recent Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) news were published by: Forbes.com which released: “ARIAD Pharmaceuticals Reaches Analyst Target Price” on September 15, 2016. Also Prnewswire.com published the news titled: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on October 07, 2016. Prnewswire.com‘s news article titled: “SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of …” with publication date: October 07, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.